(Q52968858)

English

Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.

scientific article published on 7 February 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

phase I clinical trial

0 references

author name string

Masanori Noguchi

1

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Gaku Arai

2

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Kazumasa Matsumoto

3

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Seiji Naito

4

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Fukuko Moriya

5

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Shigetaka Suekane

6

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Nobukazu Komatsu

7

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Satoko Matsueda

8

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Tetsuro Sasada

9

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Akira Yamada

10

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Tatsuyuki Kakuma

11

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Kyogo Itoh

12

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

publication date

7 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

64

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

4

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

493-505

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

https://scigraph.springernature.com/pub.10.1007/s00262-015-1660-1

0 references

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Nuclear localization of parathyroid hormone-related peptide confers resistance to anoikis in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Adjuvants designed for veterinary and human vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1660-1

21 January 2018

Identifiers

10.1007/S00262-015-1660-1

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25662406

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52968858&oldid=1749510007"